Pictet Asset Management (Switzerland)’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $123M | Buy |
648,546
+44,471
| +7% | +$8.45M | 0.15% | 176 |
|
|
2023
Q1 | $121M | Buy |
604,075
+162,513
| +37% | +$32.6M | 0.15% | 177 |
|
|
2022
Q4 | $105M | Sell |
441,562
-234,247
| -35% | -$55.7M | 0.15% | 182 |
|
|
2022
Q3 | $135M | Sell |
675,809
-5,180
| -0.8% | -$1.04M | 0.2% | 151 |
|
|
2022
Q2 | $99.3M | Buy |
680,989
+20,049
| +3% | +$2.92M | 0.14% | 201 |
|
|
2022
Q1 | $108M | Buy |
660,940
+46,948
| +8% | +$7.67M | 0.12% | 206 |
|
|
2021
Q4 | $104M | Sell |
613,992
-209,712
| -25% | -$35.6M | 0.1% | 224 |
|
|
2021
Q3 | $156M | Buy |
+823,704
| New | +$156M | 0.17% | 164 |
|